Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 12

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 12
---
 LIQUIDATION                                                                    |     |      | 113 |
| CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS OF THE                          
 LIQUIDATION                                                                    |     |      | 117 |
| PROPOSAL NO. 3 — THE LIQUIDATION                                               
 RESOLUTION                                                                     |     |      | 121 |
| PROPOSAL NO. 4 — THE LIQUIDATOR                                                
 RESOLUTION                                                                     |     |      | 122 |
| OTHER MATTERS                                                                  |     |      | 123 |
| WHERE YOU CAN FIND MORE INFORMATION                                            |     |      | 124 |
| GLOSSARY OF TERMS                                                              |     |      | 125 |
| APPROVAL OF DIRECTORS                                                          |     |      | 133 |
| Annex A ARRANGEMENT AGREEMENT                                                  |     |      | A-1 |
| Annex B FAIRNESS OPINION                                                       |     |      | B-1 |
| Annex C DISSENT RIGHTS                                                         |     |      | C-1 |
| Annex D ARRANGEMENT RESOLUTION                                                 |     |      | D-1 |
| Annex E PLAN OF ARRANGEMENT                                                    |     |      | E-1 |
| Annex F INTERIM ORDER                                                          |     |      | F-1 |
| Annex G NOTICE OF PRESENTATION                                                 |     |      | G-1 |

i

SUMMARY TERM SHEET

The following summary highlights information described in more detail elsewhere in this Circular and Proxy Statement. To understand the Arrangement and the other matters being considered at the Special Meeting more fully and for a more complete description of the legal terms of the Arrangement, you should carefully read this entire Circular and Proxy Statement, the annexes to this Circular and Proxy Statement and the documents that we refer to in this Circular and Proxy Statement. You may obtain any additional information referred to in this Circular and Proxy Statement without charge by following the instructions in the section entitled “Where You Can Find More Information.”

In this Circular and Proxy Statement, the terms “we,” “us,” “our,” the “Company” refer to Repare Therapeutics Inc. Other defined terms used in this Circular and Proxy Statement are defined in the section entitled “Glossary of Terms” of this Circular and Proxy Statement.

The Parties to the Arrangement

Repare Therapeutics Inc.

The
Company is a company incorporated under the Laws of Québec, Canada. The head office of the Company is located at 7171 Frederick